Journal
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Volume 9, Issue 3, Pages 231-234Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920108784567317
Keywords
RNase; Onconase (R); immunoRNase; antibody-RNase fusion protein; immunotherapeutics
Ask authors/readers for more resources
Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase (R)), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with un-resectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2(nd) generation immunoRNases as promising novel anticancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available